Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 9/20 | 0.52 |
| ▸ | MEN1 | O00255 | 7/20 | 0.47 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 5/20 | 0.45 |
| ▸ | TSHR | P16473 | 4/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3906944 | 0.85 | ALK (0.51) | KMT2AMEN1MAPTTSHRHPGD | |
| SCHEMBL27900546 | 0.83 | KMT2A (0.50) | KMT2AMEN1GRM2MAPTTSHR | |
| SCHEMBL13769135 | 0.83 | KMT2A (0.50) | KMT2AMEN1GRM2MAPTTSHR | |
| SCHEMBL939169 | 0.82 | ALK (0.59) | KMT2AMEN1MAPTTSHRALDH1A1 | |
| SCHEMBL183879 | 0.81 | CYP1A2 (0.48) | KMT2AMEN1TSHRALDH1A1KDM4E | |
| SCHEMBL1084260 | 0.81 | CYP2D6 (0.55) | KMT2AMEN1MAPTTSHRALDH1A1 | |
| SCHEMBL1084199 | 0.81 | KMT2A (0.57) | KMT2AMEN1MAPTTSHRALDH1A1 | |
| SCHEMBL1623862 | 0.81 | GRM2 (0.38) | KMT2AMEN1GRM2MAPTNPSR1 | |
| SCHEMBL183852 | 0.79 | PTGES (0.40) | KMT2AMEN1GRM2MAPTTSHR | |
| SCHEMBL16885076 | 0.78 | GRM2 (0.39) | KMT2AGRM2NPSR1KDM4ENPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8809353-B2 | Quinazolines useful as modulators of voltage gated ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-08-19 | — | — | US | disclosed |
| US-8809353-B2 | Quinazolines useful as modulators of voltage gated ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-08-19 | — | — | US | disclosed |
| US-8809353-B2 | Quinazolines useful as modulators of voltage gated ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-08-19 | — | — | US | disclosed |
| US-8343980-B2 | Quinazoles useful as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-01-01 | — | — | US | disclosed |
| US-8343980-B2 | Quinazoles useful as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-01-01 | — | — | US | disclosed |
| US-8343980-B2 | Quinazoles useful as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-01-01 | — | — | US | disclosed |
| CN-101068794-B | Quinazolines useful as modulators of ion channels | VERTEX PHARMA | 2012-12-19 | — | — | CN | disclosed |
| US-8283354-B2 | Voltage gated sodium and calcium channel inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-10-09 | — | — | US | disclosed |
| US-8283354-B2 | Voltage gated sodium and calcium channel inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-10-09 | — | — | US | disclosed |
| US-8283354-B2 | Voltage gated sodium and calcium channel inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-10-09 | — | — | US | disclosed |
| EP-1784393-A1 | QUINAZOLINES USEFUL AS MODULATORS OF ION CHANNELS | Vertex Pharmaceuticals Incorporated (US) | 2007-05-16 | — | — | EP | disclosed |
| US-20060217377-A1 | Quinazolines useful as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED | 2006-09-28 | — | — | US | disclosed |
| US-20060173018-A1 | Quinazolines useful as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED | 2006-08-03 | — | — | US | disclosed |
| WO-2006028904-A9 | QUINAZOLINES USEFUL AS MODULATORS OF ION CHANNELS | VERTEX PHARMA (US) | 2006-06-22 | — | — | WO | disclosed |
| CN-1784391-A | Quinazolines useful as modulators of ion channels | VERTEX PHARMA (US) | 2006-06-07 | — | — | CN | disclosed |
| WO-2006028904-A1 | QUINAZOLINES USEFUL AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2006-03-16 | — | — | WO | disclosed |
| EP-1608632-A1 | QUINAZOLINES USEFUL AS MODULATORS OF ION CHANNELS | Vertex Pharmaceuticals Incorporated (US) | 2005-12-28 | — | — | EP | disclosed |
| US-20040248890-A1 | Quinazolines useful as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED | 2004-12-09 | — | — | US | disclosed |
| WO-2004078733-A1 | QUINAZOLINES USEFUL AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2004-09-16 | — | — | WO | disclosed |
| WO-2004078733-A1 | QUINAZOLINES USEFUL AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2004-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060173018-A1 | Quinazolines useful as modulators of ion channels | KCNQ1, KCNQ2, KCNN3 | KMT2A 2404/4885MEN1 2548/4885GRM2 497/4885 |
| US-20040248890-A1 | Quinazolines useful as modulators of ion channels | KCNN3, KCNN2, CACNA1I | KMT2A 2608/4885MEN1 2516/4885GRM2 455/4885 |
| US-20060217377-A1 | Quinazolines useful as modulators of ion channels | KCNN3, KCNN2, CACNA1I | KMT2A 2608/4885MEN1 2516/4885GRM2 455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.